Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCAST: Candesartan in Acute Stroke
NCT00120003Phase 3Completed
- Sponsor
- Ullevål University Hospital
- Start
- Jun 2005
- Primary completion
- Sep 2010
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute stroke comparing Candesartan Cilexetil with Placebo (2 arms). Primary endpoints: Death or major disability (modified Rankin scale) at 6 months and Composite event of vascular death, myocardial infarction, or stroke at 6 months. Started Jun 2005; status: completed.
02
Drugs
candesartan cilexetil
03
Conditions
acute stroke
Beyond the preview
Go deeper on NCT00120003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00120003.